TMSP(SH:600671)2019-10-29 16:00Financial Performance - Net profit attributable to shareholders decreased by 77.86% to CNY 1,676,684.77 for the year-to-date period[9] - Operating revenue for the year-to-date period decreased by 24.58% to CNY 218,894,332.26 compared to the same period last year[9] - Basic earnings per share decreased by 83.33% to CNY 0.01[10] - The company reported a net loss of CNY 11,342,415.59 after deducting non-recurring gains and losses[9] - The weighted average return on equity decreased by 7.84 percentage points to 2.84%[10] - The company reported a net loss of CNY 137.55 million in 2019, compared to a loss of CNY 139.23 million in 2018, indicating a slight improvement[34] - The net profit for the first three quarters of 2019 was CNY 4,538,993.17, down 56.8% from CNY 10,509,784.50 in the same period of 2018[46] - The company reported a total loss attributable to shareholders of -¥1,359,235.27 for Q3 2019, compared to -¥2,306,657.28 in Q3 2018, showing a reduction in losses[42] Revenue and Costs - Operating revenue decreased by 24.58% to ¥218,894,332.26 from ¥290,220,477.05, attributed to the absence of other business income this year[20] - Operating costs fell by 40.02% to ¥107,284,195.89 from ¥178,876,405.83, reflecting the decrease in revenue[20] - Total operating revenue for Q3 2019 was ¥70,782,135.42, an increase from ¥67,692,224.91 in Q3 2018, representing a growth of approximately 3.1%[40] - Total operating costs for Q3 2019 were ¥73,332,317.72, compared to ¥69,237,299.92 in Q3 2018, indicating an increase of about 5.4%[41] Assets and Liabilities - Total assets increased by 14.88% to CNY 533,105,192.72 compared to the end of the previous year[9] - The company’s total assets grew from CNY 464.07 billion in 2018 to CNY 533.11 billion in 2019, marking an increase of approximately 14.9%[35] - Total liabilities increased from CNY 372.51 billion in 2018 to CNY 437.52 billion in 2019, reflecting a growth of about 17.4%[34] - The company’s total liabilities to total assets ratio stands at approximately 80.2% as of Q3 2019[54] - The company’s total liabilities to equity ratio was approximately 4.07, suggesting a high leverage position[58] - The company’s total current liabilities represented approximately 74% of total liabilities, indicating a reliance on short-term financing[58] Cash Flow - Net cash flow from operating activities increased by 431.09% to CNY 120,389,292.54 for the year-to-date period[9] - The net cash flow from financing activities decreased by 76.34 million yuan compared to last year, with a net cash outflow of 63.51 million yuan[21] - The total cash inflow from operating activities in Q3 2019 was CNY 402,973,494.09, an increase from CNY 286,517,565.10 in Q3 2018[48] - The company raised CNY 112,100,000.00 through borrowings in Q3 2019, compared to CNY 102,100,000.00 in Q3 2018[48] Shareholder Information - The total number of shareholders reached 19,509[14] - The largest shareholder, Great Wall Film and Television Culture Group, holds 27.25% of shares[14] - The total equity attributable to shareholders increased from CNY 58.23 million in 2018 to CNY 59.91 million in 2019, a growth of approximately 2.9%[35] Research and Development - Research and development expenses increased by 628.13% to ¥1,430,905.38 from ¥196,517.00, driven by costs related to the consistency evaluation of a new drug[20] - Research and development expenses for Q3 2019 were ¥560,732.48, significantly higher than ¥87,835.08 in Q3 2018, reflecting a focus on innovation[41] Investments and Future Plans - The company invested 14 million yuan to establish the Xishuangbanna Great Wall Health Industry Park, holding a 9.33% stake[21] - The company plans to invest 75 million yuan for GMP renovations in the new factory, with the first phase expected to be completed by the end of December 2019[26] - The company signed a 60 million yuan agreement to acquire 100% equity of Yinchuan Xixia, constituting a major asset restructuring[22]